Buzzi Unicem SpA announces that during the period from December 5, 2018 through December 7, 2018 it acquired no. 375,533 ordinary treasury shares for a total consideration of 6,028,141.05 Euro, as authorized by the Ordinary General Meeting on May 10, 2018.
Details of the daily transactions on the Mercato Telematico Azionario are as follows:
Date
Number of ordinary shares purchased
Average price (Euro)
Consideration (Euro)
12/05/2018
170,850
16.3508
2,793,534.18
12/06/2018
165,100
15.7804
2,605,344.04
12/07/2018
39,583
15.8973
629,262.83
Total
375,533
16.0522
6,028,141.05
Attached to this press release is a daily recap of the purchase transactions carried out during the reference period.
The Company announces also the conclusion of the share buyback program up to 7 million ordinary shares equal to 4.23% of the issued ordinary share capital.
Following the above purchases, the Company holds no. 7,050,000 ordinary shares and no. 29,290 saving shares as of December 7, 2018, equal to 3.44% of the issued share capital.
Buzzi Unicem S.p.A. published this content on 10 December 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 10 December 2018 11:19:06 UTC
Buzzi SpA, formerly known as Buzzi Unicem SpA, is an Italy-based company engaged in the manufacture of construction materials. The Company is primarily active in the production, distribution, and sale of cement, ready-mix concrete, and natural aggregates. The Companyâs operations are located in Italy, the United States, Germany, Luxembourg and the Netherlands, Poland, the Czech Republic and Slovakia, Ukraine, Russia, Mexico, Brazil, and Algeria. The three main geographical area with the higher generation of revenues are: the United States, Germany, and Mexico. The Firm is also engaged in the activity of Research and Development with the aim of developing and experimenting innovations to be used in the production chain and for their products. This activity is performed in cooperation with national research centers, universities, and private laboratories.